Nkarta, INC

Nkarta, Inc. stockholders re-elected two Class III directors and ratified the appointment of Ernst & Young LLP at the 2026 Annual Meeting.

Nkarta announced first quarter 2026 financial results, highlighting progress in its NKX019 clinical program for autoimmune diseases and a cash runway extending into 2029.

Nkarta, Inc. announced its fourth quarter and full year 2025 financial results, highlighting advancement of its NKX019 clinical program and an extended cash runway into 2029.

Nkarta, Inc. announced its third quarter 2025 financial results, highlighting clinical progress for NKX019 in autoimmune diseases and extending its cash runway into 2029.

Nkarta, Inc. announced its second quarter 2025 financial results, reporting a reduced net loss and extending its cash runway into 2029, alongside progress in its NKX019 autoimmune clinical programs.

Nkarta, Inc. announced a significant leadership transition with the appointment of Shawn Rose as Chief Medical Officer and Head of R&D, signaling a strategic pivot towards autoimmune disease, alongside the ratification of director elections and auditor appointment at its annual meeting.

Nkarta, Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $27.8 million and continued investment in its lead CAR NK cell therapy candidate, NKX019, for autoimmune diseases.

Nkarta, Inc. reported a strategic pivot to focus on autoimmune disease therapies, reducing operating losses and detailing clinical progress for its lead candidate NKX019, while acknowledging ongoing capital needs.

Nkarta, Inc. reported continued net losses in Q2 2025, alongside a strategic pivot to prioritize autoimmune disease programs and a significant workforce reduction.

Nkarta, Inc. announces its Q1 2025 financial results, highlighting a net loss of $31.98 million and providing updates on its clinical development programs, including the addition of primary membranous nephropathy (pMN) as an indication to its Ntrust-1 clinical trial.

Nkarta, Inc. reported its third quarter 2024 financial results and announced a strategic shift to focus on autoimmune disease, deprioritizing its B-cell malignancy programs.

Nkarta Inc. reported its second quarter 2024 financial results, highlighting progress in its clinical programs and financial position.

Nkarta, Inc. reports a strategic pivot to autoimmune disease therapies with its lead candidate NKX019, alongside reduced net losses and a strong cash position for the next 12 months.

Nkarta's 2024 10-K filing highlights a strategic shift towards autoimmune disease therapies, particularly NKX019, while managing financial resources through cost-containment measures and capital raising.

Nkarta, Inc.'s 10-K filing details the company's capital structure, ongoing clinical trials, and strategic focus on developing allogeneic NK cell therapies for autoimmune diseases and cancer.

Nkarta, Inc. reports that Director Ali Behbahani acquired stock options for 37,000 shares of common stock.

Nkarta, Inc. reports that Director George Simeon acquired stock options for 37,000 shares of common stock.

Nkarta, Inc. Director George Vratsanos reported the acquisition of stock options for 37,000 shares of common stock.

Nkarta, Inc. reports that Director Zachary Scheiner was granted a stock option for 37,000 shares with an exercise price of $2.46.

Nkarta, Inc. reports that Director Leone D. Patterson was granted stock options for 37,000 shares.

Nkarta, Inc. reports that Director Michael Dybbs acquired 37,000 stock options with an exercise price of $2.46.

Nkarta, Inc. has issued its 2026 proxy statement detailing the upcoming virtual annual meeting, director elections, and executive compensation proposals.

Nkarta, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pertaining to its upcoming shareholder meeting.

Nkarta, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, to elect directors and ratify the appointment of Ernst & Young LLP as the independent accounting firm.

Nkarta, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pertaining to its upcoming shareholder meeting.

Nkarta, Inc. is holding its annual meeting on June 13, 2024, to vote on director elections, auditor ratification, and an increase in authorized common stock.

New Enterprise Associates 15, L.P. and affiliated entities have filed an amendment to their Schedule 13D, reporting a decrease in beneficial ownership of Nkarta, Inc. common stock to below 5%.

Samsara BioCapital and its affiliates have reduced their beneficial ownership in NKARTA, INC. to 4.9%, falling below the 5% threshold.

LSP 6 Management B.V. and its affiliated entities have filed an Amendment No. 2 to Schedule 13D, reporting that their beneficial ownership in Nkarta, Inc. has decreased to 4.0% of outstanding common stock, falling below the 5% reporting threshold.

Citadel entities and Kenneth Griffin have disclosed their beneficial ownership in Nkarta, Inc., with Griffin holding an aggregate of 4.1% of the common stock.

BlackRock, Inc. reported a 4.96% beneficial ownership stake in Nkarta, Inc. common stock as of September 30, 2025, as detailed in its Schedule 13G/A filing.

Commodore Capital LP and Commodore Capital Master LP have filed an amended Schedule 13G, reporting a reduction in their beneficial ownership of Nkarta, Inc.'s common stock to 0.5% as of December 31, 2024.

Adage Capital Management, L.P. and its affiliated entities have reported a complete divestment of their beneficial ownership in Nkarta, Inc., reducing their stake to 0% as of December 31, 2024.

Tang Capital Management, LLC and affiliated entities, including Kevin Tang, have reported a collective beneficial ownership of 9.9% in Nkarta, Inc.'s common stock.